Rivulet Prostate cancer bone metastasis belongs to stage IV (late stage). The staging of prostate cancer is mainly based on the degree of tumor spread. Bone metastasis usually indicates that the tumor has broken through the local scope and metastasized to distant sites. The clinical staging is M1 in the TNM system.
When prostate cancer cells metastasize to bones through the blood or lymphatic system, this stage falls into the category of distant metastasis. Common sites of metastasis include weight-bearing bones such as the spine, pelvis, ribs, and hips. Imaging examinations such as bone scan, CT or MRI can determine the location and scope of bone metastases. Symptoms such as bone pain, pathological fractures, and spinal cord compression may occur at this stage. The treatment goals shift to controlling disease progression, alleviating symptoms, and improving quality of life. Treatment options typically include endocrine therapy combined with bone-protecting drugs such as zoledronic acid injection or denosumab injection. Radionuclide therapy such as radium-223 dichloride can be used to relieve pain from multiple bone metastases. If necessary, local radiation therapy is given to the weight-bearing bones to prevent fractures.
Patients with prostate cancer bone metastases should maintain moderate activity to maintain bone density, avoid high-calcium diets and monitor blood calcium levels regularly. In pain management, it is necessary to use analgesics in accordance with the doctor's instructions and pay attention to psychological support and nutritional conditioning. It is recommended that family members assist in recording symptom changes and accompany them for regular review.
